Catalent (CTLT) has risen sharply, recording gains of 2.54% in the past 4 weeks. However, the stock has corrected -2.88% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.5% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.43% and the 50-Day Moving Average is 2.71%. Catalent (NYSE:CTLT): On Fridays trading session , Opening price of the stock was $25.18 with an intraday high of $25.35. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $24.53. However, the stock managed to close at $24.6, a loss of 2.92% for the day. On the previous day, the stock had closed at $25.34. The total traded volume of the day was 905,663 shares.
The company Insiders own 0.98% of Catalent shares according to the proxy statements. Institutional Investors own 99.72% of Catalent shares. Also, In the latest statement by the brokerage house, Wells Fargo upgrades its outlook on Catalent (NYSE:CTLT). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Market Perform. The rating by the firm was issued on June 21, 2016.
Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.